Biohaven Pharmaceutical (NYSE:BHVN) has been given a $48.00 price target by research analysts at Piper Jaffray Companies in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the stock. Piper Jaffray Companies’ price target indicates a potential upside of 128.46% from the stock’s current price.

A number of other equities analysts have also commented on the company. Zacks Investment Research raised Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Monday, December 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price target on shares of Biohaven Pharmaceutical in a research note on Wednesday, November 15th. BidaskClub lowered Biohaven Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. William Blair reaffirmed an “outperform” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, October 3rd. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $38.00 price target (down previously from $47.00) on shares of Biohaven Pharmaceutical in a research note on Tuesday, October 3rd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $37.17.

Biohaven Pharmaceutical (NYSE BHVN) opened at $21.01 on Monday. Biohaven Pharmaceutical has a one year low of $17.00 and a one year high of $39.51.

In other Biohaven Pharmaceutical news, insider Robert Berman sold 160,000 shares of the stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $25.76, for a total value of $4,121,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vlad Coric sold 150,000 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $29.41, for a total value of $4,411,500.00. The disclosure for this sale can be found here. Insiders sold 439,131 shares of company stock valued at $12,011,701 in the last quarter.

Several hedge funds have recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in shares of Biohaven Pharmaceutical during the third quarter worth about $119,000. Nationwide Fund Advisors acquired a new position in shares of Biohaven Pharmaceutical during the third quarter worth about $214,000. American International Group Inc. acquired a new position in shares of Biohaven Pharmaceutical during the third quarter worth about $251,000. State of Wisconsin Investment Board acquired a new position in Biohaven Pharmaceutical during the third quarter valued at approximately $262,000. Finally, Susquehanna International Group LLP acquired a new position in Biohaven Pharmaceutical during the third quarter valued at approximately $302,000. 47.76% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/11/biohaven-pharmaceutical-bhvn-given-a-48-00-price-target-by-piper-jaffray-companies-analysts.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.